v3.25.1
Cover Page - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Mar. 27, 2025
Jun. 28, 2024
Document Information [Line Items]      
Document Type 10-K/A    
Amendment Flag true    
Document Period End Date Dec. 31, 2024    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Trading Symbol RNTX    
Entity Registrant Name Rein Therapeutics, Inc.    
Entity Central Index Key 0001420565    
Current Fiscal Year End Date --12-31    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
ICFR Auditor Attestation Flag false    
Entity Common Stock, Shares Outstanding   21,992,387  
Entity Public Float     $ 54,077,680
Entity File Number 001-38130    
Entity Tax Identification Number 13-4196017    
Entity Address, Address Line One 12407 N. Mopac Expy    
Entity Address, Address Line Two Suite 250    
Entity Address, Address Line Three #390    
Entity Address, City or Town Austin    
Entity Address, State or Province TX    
Entity Address, Postal Zip Code 78758    
City Area Code 737    
Local Phone Number 802-1989    
Entity Incorporation, State or Country Code DE    
Document Annual Report true    
Document Transition Report false    
Title of 12(b) Security Common Stock, $0.001 par value    
Security Exchange Name NASDAQ    
Document Financial Statement Error Correction [Flag] false    
Amendment Description This Amendment No. 1 on Form 10-K/A (this “Amendment”) is filed with respect to our Annual Report on Form 10-K for the year ended December 31, 2024 (the “Original Filing”), filed with the Securities and Exchange Commission (the “SEC”) on April 7, 2025. We are filing this Amendment solely for the purpose of including the information required by Part III of Form 10-K, which information was omitted from the Original Filing in reliance on General Instruction G(3) to Form 10-K, which permits the information required by Part III of Form 10-K to be incorporated by reference from a registrant’s definitive proxy statement if it is filed with the SEC no later than 120 days after the fiscal year end. However, we do not intend to file a definitive proxy statement for our 2025 annual meeting of stockholders within 120 days of the end of our fiscal year ended December 31, 2024. Accordingly, this Amendment is being filed solely to (i) provide the information required by Items 10 through 14 of Part III of the Original Filing, and (ii) delete the reference on the cover page of the Original Filing to the incorporation by reference of portions of our definitive proxy statement into Part III of the Original Filing. In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), new certifications by our principal executive officer and principal financial officer are filed herewith as exhibits to this Amendment pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act. This Amendment speaks as of the date of the Original Filing and, except as described above, this Amendment makes no changes to the Original Filing. This Amendment does not amend, update or change the financial statements or any other information presented in the Original Filing and does not otherwise reflect events occurring after the date of the Original Filing. Accordingly, this Amendment should be read in conjunction with our filings with the SEC subsequent to the filing of the Original Filing. Unless indicated otherwise, throughout this Amendment, references to “Rein,” “the Company,” “we,” “us” and “our” refer to Rein Therapeutics, Inc. and its subsidiaries, except where the context otherwise requires or indicates. Rein and the other trademarks or service marks of Rein appearing in this Amendment are the property of Rein. All other trademarks, service marks or other trade names appearing in this Amendment are the property of their respective owners.